Alakhova Daria Y, Kabanov Alexander V
Center for Nanotechnology in Drug Delivery and Division of Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina 27599-7362, United States.
Mol Pharm. 2014 Aug 4;11(8):2566-78. doi: 10.1021/mp500298q. Epub 2014 Jul 10.
Multidrug resistance (MDR) remains one of the biggest obstacles for effective cancer therapy. Currently there are only few methods that are available clinically that are used to bypass MDR with very limited success. In this review we describe how MDR can be overcome by a simple yet effective approach of using amphiphilic block copolymers. Triblock copolymers of poly(ethylene oxide) (PEO) and poly(propylene oxide) (PPO), arranged in a triblock structure PEO-PPO-PEO, Pluronics or "poloxamers", raised a considerable interest in the drug delivery field. Previous studies demonstrated that Pluronics sensitize MDR cancer cells resulting in increased cytotoxic activity of Dox, paclitaxel, and other drugs by 2-3 orders of magnitude. Pluronics can also prevent the development of MDR in vitro and in vivo. Additionally, promising results of clinical studies of Dox/Pluronic formulation reinforced the need to ascertain a thorough understanding of Pluronic effects in tumors. These effects are extremely comprehensive and appear on the level of plasma membranes, mitochondria, and regulation of gene expression selectively in MDR cancer cells. Moreover, it has been demonstrated recently that Pluronics can effectively deplete tumorigenic intrinsically drug-resistant cancer stem cells (CSC). Interestingly, sensitization of MDR and inhibition of drug efflux transporters is not specific or selective to Pluronics. Other amphiphilic polymers have shown similar activities in various experimental models. This review summarizes recent advances of understanding the Pluronic effects in sensitization and prevention of MDR.
多药耐药性(MDR)仍然是有效癌症治疗的最大障碍之一。目前临床上仅有少数方法可用于绕过MDR,但成功率非常有限。在本综述中,我们描述了如何通过使用两亲性嵌段共聚物这种简单而有效的方法来克服MDR。聚环氧乙烷(PEO)和聚环氧丙烷(PPO)的三嵌段共聚物,以PEO-PPO-PEO三嵌段结构排列,即普朗尼克(Pluronics)或“泊洛沙姆”(poloxamers),在药物递送领域引起了相当大的关注。先前的研究表明,普朗尼克可使MDR癌细胞敏感化,导致阿霉素、紫杉醇和其他药物的细胞毒性活性提高2至3个数量级。普朗尼克还可在体外和体内预防MDR的发生。此外,阿霉素/普朗尼克制剂临床研究的 promising 结果强化了全面了解普朗尼克在肿瘤中的作用的必要性。这些作用极其全面,出现在MDR癌细胞的质膜、线粒体和基因表达调控水平上。此外,最近已证明普朗尼克可有效清除具有肿瘤igenic的内在耐药性癌症干细胞(CSC)。有趣的是,MDR的敏感化和药物外排转运蛋白的抑制对普朗尼克并非特异性或选择性的。其他两亲性聚合物在各种实验模型中也显示出类似的活性。本综述总结了在理解普朗尼克在MDR敏感化和预防方面的作用的最新进展。